Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Krystal Biotech Inc (NQ: KRYS )

190.40 +8.11 (+4.45%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech Inc

< Previous 1 2 3 4 Next >
A Preview Of Krystal Biotech's Earnings
Via Benzinga
AI, Biotech, Energy Sectors Expect M&A Revival For 2024
The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Expert Ratings for Krystal Biotech
Via Benzinga
This Stock Has Quadrupled in 5 Years. Can It Do It Again?
Have investors already missed the boat with this stock? 
Via The Motley Fool
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
A Preview Of Krystal Biotech's Earnings
Via Benzinga
5 Analysts Have This to Say About Krystal Biotech
Via Benzinga
5 Analysts Have This to Say About Krystal Biotech
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
Via Benzinga
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
Exposures Product Safety
Analyst Ratings for Krystal Biotech
Via Benzinga
Expert Ratings for Krystal Biotech
Via Benzinga
What Will AbbVie Buy Next?
Two mid-cap drugmakers stand out as logical targets for AbbVie. 
Via The Motley Fool
Krystal Biotech Inc. (NASDAQ: KRYS) is a Stock Spotlight on 6/8
Via Investor Brand Network
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2023
Via Benzinga
Krystal Biotech Sells Rare Pediatric Disease Priority Review Voucher For $100M
Krystal Biotech, Inc. (NASDAQ: KRYS) has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV)  
Via Benzinga
3 Biotech Stocks to Buy Before the Breakout
Explosive growth and rapid innovation lie ahead for these three biotechnology stocks, making them the ones to watch. 
Via InvestorPlace
Up 48% in 2023, Is This Biotech Stock a Buy?
How much longer can this biotech's run last? 
Via The Motley Fool
Why Shares of Krystal Biotech Are Rising Monday
The company is moving quickly to market its newly approved therapy. 
Via The Motley Fool
Analyst Expectations for Krystal Biotech's Future
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023
Via Benzinga
2 Soaring Stocks With More Upside Potential
Are these mid-cap stocks giants in the making? 
Via The Motley Fool
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
Arbutus Appoints Two New Executives
From Arbutus Biopharma Corporation
Via GlobeNewswire
Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
Regulatory momentum, bullish Wall Street analysts and favorable technicals all suggest Krystal Biotech, Inc. may be a gem. 
Via MarketBeat
Exposures Product Safety
Option Care Health Selected by Krystal Biotech as Part of a Limited Distribution Specialty Pharmacy Network for VYJUVEK™
From Option Care Health, Inc.
Via GlobeNewswire
Unlocking a $750 Million Opportunity: Krystal Biotech's Vyjuvek and its Potent Impact on Dystrophic Epidermolysis Bullosa Treatment
The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for treating patients six months of age or older with  
Via Benzinga
Krystal Biotech Inc. (NASDAQ: KRYS) Highlighted for Surprising Price Action
Via Investor Brand Network
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.